Lipanthyl Nt

Fenofibrate, the active ingredient in Lipanthyl Nt, is a fibrate presented as a nanonised oral tablet for oral use. It lowers elevated triglyceride levels and modifies lipid profiles in adults with dyslipidaemia. It is prescribed when lifestyle changes alone are insufficient to achieve target lipid levels.

GNH USA supplies Lipanthyl Nt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions.

Fenofibrate acts on triglyceride‑rich lipoproteins to improve lipid abnormalities in several dyslipidaemia disorders.

- Hypertriglyceridaemia: reduces serum triglyceride concentrations and lowers risk of pancreatitis. - Mixed dyslipidaemia: decreases triglycerides while modestly raising HDL‑cholesterol. - Primary hypercholesterolaemia (adjunct therapy): complements statin treatment to further improve lipid profile.

Fenofibrate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: transient increase in ALT or AST. - Dizziness or vertigo. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Pancreatitis: inflammation of the pancreas. - Severe hypersensitivity: rash, angioedema or anaphylaxis. - Myopathy with renal impairment: muscle weakness with kidney dysfunction.

Before initiating fenofibrate therapy, several safety considerations should be reviewed. - Liver function monitoring: assess baseline enzymes and repeat periodically. - Renal function assessment: evaluate creatinine clearance, especially in the elderly. - Gallstone risk: avoid in patients with active biliary disease. - Concomitant statin use: limit dose and monitor for myopathy. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store at room temperature: keep in original container, protect from moisture and heat.

Fenofibrate can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Gemfibrozil: combined use markedly increases risk of rhabdomyolysis. - Cyclosporine: may raise fenofibrate plasma levels, enhancing toxicity. - High‑dose statins (e.g., rosuvastatin >20 mg): increased incidence of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: fenofibrate may potentiate anticoagulant effect, requiring INR monitoring. - Oral hypoglycemics: may enhance glucose‑lowering effect, risk of hypoglycaemia.